MannKind Corporation (NASDAQ: MNKD)

MannKind Corporation (NASDAQ: MNKD), a biopharmaceutical company, has focused their efforts on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Technosphere® Insulin System, the company’s lead investigational product candidate, is currently in Phase 3 clinical trials in the U.S., Europe and Latin America. MannKind believes the Technosphere® Insulin System has the potential to revolutionize the way diabetes is treated. For further information, visit the Company’s web site at www.mannkindcorp.com.